cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Bayu Brahma
Contact Email
journal.cancer@gmail.com
Phone
+628176389956
Journal Mail Official
admin@indonesianjournalofcancer.or.id
Editorial Address
National Cancer Center - Dharmais Cancer Hospital Research and Development Building, 3rd-floor Jl. Letjen S. Parman Kav. 84-86, Slipi West Jakarta
Location
Kota adm. jakarta barat,
Dki jakarta
INDONESIA
Indonesian Journal of Cancer
Published by National Cancer Center-Dharmais Cancer Hospital
ISSN : 19783744     EISSN : 23556811     DOI : https://www.doi.org/ 10.33371
Core Subject : Health, Science,
Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Public Health
Indonesian Journal of Cancer is a peer-reviewed and open-access journal. This journal is published quarterly (in March, June, September, and December) by Dharmais Cancer Hospital - National Cancer Center. Submissions are reviewed under a broad scope of topics relevant to experimental and clinical cancer research. Articles are original research that needs to be disseminated and written in English. All submitted manuscripts will go through the double-blind peer review and editorial review before being granted acceptance for publication. The journal publishes original research articles, case reports, and review articles under the following categories: cancer management, cancer prevention, cancer etiology, epidemiology, molecular oncology, cancer diagnosis and therapy, tumor pathology, surgical oncology, medical oncology, radiation oncology, interventional radiology, as well as early detection.
Arjuna Subject : Kedokteran - Onkologi
Articles 3 Documents
 1 
Search results for , issue "Vol 9, No 2 (2015): April-Juni 2015" : 3 Documents clear
Pregnancy Associated Breast Cancer di Rumah Sakit Onkologi Surabaya 2006 2014 JACOBUS OCTOVIANUS; SAVITRI KUNTARI; ARIO DJATMIKO
Indonesian Journal of Cancer Vol 9, No 2 (2015): April-Juni 2015
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (622.646 KB) | DOI: 10.33371/ijoc.v9i2.377

Abstract

ABSTRACTPregnancy associated breast cancer (PABC) is the most common malignancy in gestation. Due to its high aggressiveness, PABC needs a specific management right from diagnosis process to therapy. The objective of this study is to find out the PABC profile in Rumah Sakit Onkologi Surabaya from 2006-2014. A descriptive study using PABC Medical Record datafrom 2006 until 2014. There were 21 PABC patients of whom 11 was diagnosed on 31-40 years old (52.38%); 16 PABC patients with multiparity (76.19%); 14 (66.67%) PABC diagnosed at 1 year post partum; 18 USG and 6 Mammography examinations, both revealed 100% sensitivity in diagnosing PABC; 14 patients (66,67%) in stadium III-IV; 9 patients (42,86%) with T4 tumor size; 9 patients (42,86%) with axillary lymphnode metastasis ; 4 patients (19,05%) with distant metastasis; 10 patients (47,62%) with Invasive Ductal Carcinoma (IDC); 14 patients (66,67%) grade III; and 8 patients (38,10%) with angioinvasion. Positive ER/PR in 11 patients (52,38%) and positive Her-2 in 10 patients (47,62%). PABC prognosis were: 8 patients (38,10%) in good condition, while 5 patients (23.81%) had distant metastasis, and 4 patients (19,05%) passed away. Twenty one babies born healthy (100%). The aggressiveness of PABC can be seen from the percentage of patients in advanced stage and has worse prognosis.Keywords: breast cancer, pregnancyABSTRAKPregnancy Associated Breast Cancer (PABC) merupakan keganasan yang paling sering ditemukan pada kehamilan. Karena agresivitas yang tinggi, PABC memerlukan penanganan yang khusus, baik saat penegakan diagnosis maupun tindakan terapi. Penelitian ini bertujuan mengetahui profil PABC di Rumah Sakit Onkologi Surabaya sejak 2006-2014. Studi deskriptif ini menggunakan data rekam medis pasien PABC sejak 2006 hingga 2014. Hasil penelitian menunjukkan kasus PABC sebanyak 21 pasien. Jumlah PABC tertinggi ditemukan pada usia 31-40 tahun, yaitu 11 pasien (52,38%); 16 pasien (76,19%) PABC didapatkan pada multiparitas; 14 pasien (66,67%) pada 1 tahun post-partum. Pada 18 pemeriksaan USG dan 6 pemeriksaan mammografi memiliki tingkat sensitivitas 100%; 14 pasien (66,67%) pada stadium III-IV; 9 pasien (42,86%) tumor T4; 12 pasien (57,14%) metastasis ke kelenjar getah bening; 4 pasien (19,05%) metastasis jauh; 10 pasien (47,62%) Invasive Ductal Carcinoma (IDC); 14 pasien (66,67%) pada grade III; 8 pasien (38,10%) memiliki angioinvasion; 11 pasien (52,38%) memiliki ER/PR positif; dan 10 pasien (47,62%) memiliki Her-2 positif. Pada follow up didapatkan 8 pasien (38,10%) berada dalam kondisi baik, 5 pasien mengalami metastasis jauh (23,81%), dan 4 pasien meninggal (19,05%). Dua puluh satu bayi terlahir sehat (100%). Kesimpulannya, agresivitas PABC dapat dilihat dari besarnya persentase pasien yang datang pada stadium lanjut dan prognosis yang buruk.Kata Kunci: kanker payudara, kehamilan
Perbandingan Uji Diagnostik Mesothelin Serum dengan CA-125 pada Kanker Ovarium Tipe Epitel ERI PERDANA USHAN; BRAHMANA ASKANDAR T; BUDIONO BUDIONO
Indonesian Journal of Cancer Vol 9, No 2 (2015): April-Juni 2015
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1314.123 KB) | DOI: 10.33371/ijoc.v9i2.379

Abstract

This study was conducted to determine and compare the sensitivity, specificity, PPA and NPV of Mesothelin tumor marker, CA-125, combination of Mesothelin and CA-125 as a tumor marker in patients with epithelial ovarian carcinoma. This is a cross sectional diagnostic test on 30 subjects with malignant dan 30 sunjects with benign ovarian tumors that meet the inclusion and exclusion of research criteria in Department of Obstetrics and Gynecology, Medical Faculty Airlangga University/Dr. Soetomo, Surabaya. Blood sample were taken prior to surgery to examine tumor markers (Mesothelin and CA-125) and ultrasound to evaluate tumor mass, and then histopathology of surgery specimen. Statistical data calculated using SPSS. There is a significant increase of Mesothelin serum level and can be used as a tumor marker (alone or in combination with other methods as a triage tool, consider the use of new cut-off value of 1.75 nmol/L). Sensitivity, specificity, PPV, NPV of CA125 is 70%, 33.3%, 51.2% and 52.6%. Sensitivity, specificity, PPV, NPV of Mesothelin-1 is 50%, 80%, 71.4% and 61.5%. Sensitivity, specificity, PPV, NPV of Mesothelin-2 is 36.7%, 93.4%, 84.6% and 59.6%. Sensitivity, specificit , PPV, NPV combination of CA-125 + Mesothelin-1 is 33.3%, 86.7%, 71.4%, 56.5% and 60%. Sensitivity, specificity, PPV, NPV combination of CA-125 + Mesothelin-2 is 23.3%, 93.3%, 77.8%, and 54.9%. Sensitivity, specificity, PPV, NPV of RMI is 83.3%, 36.7%, 56.8%, and 68.8%. CA-125 (as a single tumor marker) has the highest sensitivity and proved as a simple and effective method for the early detection at general population. Mesothelin-2 (either as a single tumor marker or in combination) is more appropriate for the diagnosis tools (triage, determining the risk of malignant from benign ovarian masses) are better than the current and can be considered to replace CA-125.Keywords: tumor marker, CA-125, Mesothelin, combine tumor marker.ABSTRAKPenelitian ini bertujuan mengetahui dan membandingkan sensitivitas, spesifisitas, PPV, dan NPV antara penanda tumor Mesothelin, CA-125, dan kombinasi Mesothelin dan CA-125 sebagai penanda tumor pada penderita keganasan ovarium tipe epitel. Penelitian ini merupakan uji diagnostik cross sectional terhadap 30 pasien tumor jinak dan 30 pasien tumor ganas tumor ovarium yang memenuhi kriteria inklusi dan kriteria eksklusi di Bagian Obstetri dan Ginekologi FK-Unair/RSU Dr. Soetomo, Surabaya. Dilakukan pengambilan serum darah untuk memeriksa tumor marker (Mesothelin dan CA-125) dan pemeriksaan ultrasonografi sebelum dilakukan tindakan pembedahan. Kemudian dilakukan pemeriksaan patologi anatomi spesimen operasi. Penghitungan data statistik menggunakan SPSS. Hasil penelitian menunjukkan terdapat peningkatan kadar serum Mesothelin yang dapat digunakan sebagai pemeriksaan penanda tumor tunggal atau kombinasi sebagai alat triase dengan mempertimbangkan penggunaan nilai cut-off 1,75 nmol/L. Sensitivitas, spesifisitas, PPV, dan NPV CA125 adalah 70%; 33,3%; 51,2%; dan 52,6%. Sensitivitas, spesifisitas, PPV, dan NPV Mesothelin-1 adalah 50%; 80%; 71,4%; dan 61,5%. Sensitivitas, spesifisitas, PPV, dan NPV Mesothelin-2 adalah 36,7%; 93,4%; 84,6%; dan 59,6%. Sensitivitas, spesifisitas, PPV, dan NPV kombinasi CA-125 + Mesothelin-1 adalah 33,3%; 86,7%; 71,4%; 56,5%; dan 60%. Sensitivitas, spesifisitas, PPV, dan NPV kombinasi CA-125 + Mesothelin-2 adalah 23,3%; 93,3%; 77,8%; dan 54,9%. CA-125 (sebagai penanda tumor tunggal) memiliki sensitivitas tertinggi sehingga merupakan metode sederhana dan efektif untuk deteksi dini pada populasi. Mesothelin-2 (baik sebagai penanda tumor tunggal maupun dalam kombinasi) lebih tepat untuk proses penegakan diagnosis (triase, penentuan risiko massa ovarium ganas dari jinak) yang lebih baik dan dapat menggantikan CA-125.Kata Kunci: penanda tumor, CA-125, Mesothelin, kombinasi CA-125 dan Mesothelin
Analisis Drug Related Problems pada Pasien Kanker Padat Stadium Lanjut yang Menjalani Terapi Paliatif di Rumah Sakit Kanker Dharmais EMA NILLAFITA PUTRI KUSUMA
Indonesian Journal of Cancer Vol 9, No 2 (2015): April-Juni 2015
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (835.384 KB) | DOI: 10.33371/ijoc.v9i2.376

Abstract

ABSTRACTThe goal of palliative care is to increase the quality of life and to reduce the symptomp, but it often increases the complexity of patients therapy. The aim of this study is to evaluate prevalance, the risk factor, and the profile of Drug Related Problems (DRPs) from the palliative therapy patient who suffer from solid cancer at Dharmais Hospital National Cancer Center. This is a cross sectional study and the data was taken from the patients medical records starting from March to June 2011. The patient characteristics who followed this study were 33 patients women (68.8%), and the frequent cases of solid cancer was breast cancer, i.e about 15 patients (31.3%). Most of the patients (64.6%) were in palliative care. Adverse reactions occurred in 70.1% patienst and 66.2% patients got potential adverse reaction. Only 5.7% drug-drug interactions were detected with moderate significance. About 15.0% drug interactions caused by the use of morphine, and amitriptyline at the same time. The risk of incident adverse reactions were influenced by age, sex,history of curative chemotherapy regimen, comorbidities, and the number of drug use. The increasing risk of drug interaction incident was the influenced by the number of drugs using ( > 5 drugs) and if the patient had a comorbidities. Most of patients in the palliative care would get the DRP but drug interactions did not always occur.ABSTRAKTerapi paliatif bertujuan meningkatkan kualitas hidup dan mengurangi gejala, namun akan menambah kompleksitas terapi. Penelitian ini bertujuan mengevaluasi prevalensi, faktor risiko, dan profil kejadian Drug Related Problems (DRPs) terapi paliatif pasien kanker padat stadium lanjut. Penelitian ini adalah penelitian potong lintang. Dan data diambil dari rekam medis pasien bulan Maret Juni 2011. Karakteristik pasien, 33 orang (68,8%) perempuan, dan kasus kanker padat terbesar adalah kanker payudara sebanyak 15 orang (33,3%). Sebagian besar pasien kanker padat stadium lanjut (64,6%) hanya menjalani satu kali terapi paliatif. Reaksi obat yang tidak diinginkan (ROTD) termanifestasi dialami 70,1% subyek uji dan 66,2% uji berpotensi mengalami ROTD. Interaksi obat dengan signifikansi moderate ditemui pada 5,7% terapi pasien. Sebesar 15,0% interaksi tersebut akibat penggunaan morfin dan amitriptilin bersama. Risiko ROTD meningkat karena usia, jenis kelamin, riwayat pemberian regimen kemoterapi kuratif, penyakit penyerta, dan jumlah obat yang digunakan. Peningkatan risiko kejadian interaksi obat dipengaruhi oleh penggunaan > 5 jenis obat dan adanya penyakit penyerta. Pasien kanker padat stadium lanjut yang menjalani terapi paliatif pada umumnya mengalami ROTD, namun jarang ditemukan interaksi obat.

Page 1 of 1 | Total Record : 3

 1 

Filter by Year

2015 2015


Reset
Filter By Issues
All Issue Vol 17, No 3 (2023): September Vol 17, No 2 (2023): June Vol 17, No 1 (2023): March Vol 16, No 4 (2022): December Vol 16, No 3 (2022): September Vol 16, No 2 (2022): June Vol 16, No 1 (2022): March Vol 15, No 4 (2021): December Vol 15, No 3 (2021): September Vol 15, No 2 (2021): June Vol 15, No 1 (2021): March Vol 14, No 4 (2020): December Vol 14, No 3 (2020): September Vol 14, No 2 (2020): June Vol 14, No 1 (2020): March Vol 13, No 4 (2019): December Vol 13, No 3 (2019): September Vol 13, No 2 (2019): June Vol 13, No 1 (2019): March Vol 12, No 4 (2018): October-December Vol 12, No 3 (2018): July-September Vol 12, No 2 (2018): April-June Vol 12, No 1 (2018): Jan - Mar Vol 11, No 4 (2017): October- December 2017 Vol 11, No 3 (2017): July - September 2017 Vol 11, No 2 (2017): April - June Vol 11, No 1 (2017): Jan-Mar Vol 10, No 4 (2016): October - December 2016 Vol 10, No 3 (2016): July - September 2016 Vol 10, No 2 (2016): April - June 2016 Vol 10, No 1 (2016): Jan - Mar 2016 Vol 9, No 4 (2015): Okt - Des 2015 Vol 9, No 3 (2015): Jul - Sept 2015 Vol 9, No 2 (2015): April-Juni 2015 Vol 9, No 1 (2015): Jan - Mar 2015 Vol 8, No 4 (2014): Oct - Dec 2014 Vol 8, No 3 (2014): Jul - Sep 2014 Vol 8, No 2 (2014): April-Juni 2014 Vol 8, No 1 (2014): Jan - Mar 2014 Vol 7, No 4 (2013): Oct - Dec 2013 Vol 7, No 3 (2013): Jul - Sep 2013 Vol 7, No 2 (2013): Apr - Jun 2013 Vol 7, No 1 (2013): Jan - Mar 2013 Vol 6, No 4 (2012): Oct - Dec 2012 Vol 6, No 3 (2012): Jul - Sep 2012 Vol 6, No 2 (2012): Apr - Jun 2012 Vol 6, No 1 (2012): Jan - Mar 2012 Vol 5, No 4 (2011): Oct - Dec 2011 Vol 5, No 3 (2011): Jul - Sep 2011 Vol 5, No 2 (2011): Apr - Jun 2011 Vol 5, No 1 (2011): Jan - Mar 2011 Vol 4, No 4 (2010): Oct - Dec 2010 Vol 4, No 3 (2010): Jul - Sep 2010 Vol 4, No 2 (2010): Apr - Jun 2010 Vol 4, No 1 (2010): Jan - Mar 2010 Vol 3, No 4 (2009): Oct - Dec 2009 Vol 3, No 3 (2009): Jul - Sep 2009 Vol 3, No 2 (2009): Apr - Jun 2009 Vol 3, No 1 (2009): Jan - Mar 2009 Vol 2, No 4 (2008): Oct - Dec 2008 Vol 2, No 3 (2008): Jul - Sep 2008 Vol 2, No 2 (2008): Apr - Jun 2008 Vol 2, No 1 (2008): Jan - Mar 2008 Vol 1, No 4 (2007): Oct - Dec 2007 Vol 1, No 3 (2007): Jul - Sep 2007 Vol 1, No 2 (2007): Apr - Jun 2007 Vol 1, No 1 (2007): Jan - Mar 2007 More Issue